Summary
58 / 100 · Bulios Score
What speaks for it
- Out of every 100 CHF of revenue, 13 CHF is left as net profit.
- It has been profitable 6 years in a row.
What to watch
- It cut its dividend by 99% last year.
- The share price is above the Bulios Fair Price.
- It missed profit estimates 6 times in the last 8 quarters.
- Revenue grew by only 2.6% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 18.9 CHF for 1 CHF of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (CHF)
Diluted EPS (CHF)
- Analyst estimate
Revenue grew by 9.5% a year over 5 years. Over the last 3 years it grew by 2.6% a year. For the next fiscal year analysts expect revenue to grow by 4.1%. Earnings per share grew by 2.0% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 CHF of revenue goes
- Cost of sales 73 CHF
- Research and development 3.7 CHF
- Sales and administration 7.6 CHF
- Taxes and other 3.0 CHF
- Net profit 13 CHF
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 CHF
Out of every 100 CHF of revenue, 13 CHF is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 0.58%
- Paid out of profit
- 11%
You receive $0.51 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 2
- Sell 0
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.